Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with I-Mab (Nasdaq: IMAB), an innovation-driven clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel and highly differentiated biologics in the immuno-oncology therapeutic area. Under the terms of the agreement, Complix will use its proprietary Alphabody platform to deli...
Region Flamande Mark Vaeck Prnewswire Complix Taylor Guo Alphabodies Cpabs Cell Penetrating Alphabodies
Source: prnewswire.com